China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for ...

Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US.

Shares of Incyte INCY have risen 12.7% in the past six months against the industry’s decline of 0.5%. The stock has also ...

Patients with vitiligo may significantly improve the effectiveness of a commonly used light therapy — by nearly twofold— by ...

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the EADV 2024 Congress ...

Others question whether vitiligo should be celebrated rather than masked or corrected. Ruxolitinib (brand name Opzelura) must be prescribed by a doctor because the treatment requires monitoring.

On its own, vitiligo is usually not painful and is not life-threatening. Some people with the condition choose not to treat ...

Intrinsic alterations in the skin of patients with vitiligo include a thicker epidermis with a reduced number of basal melanocytes and the presence of degenerated keratinocytes with swollen ...

Vitiligo causes patches of skin with lost pigment, but it can also raise your risk of eye and skin damage from UV rays. Find out how new and old treatments may work for your vitiligo.

Vitiligo is a skin condition that can affect infants as young as 3 months old. However, it is rare for an infant to be born with vitiligo. Vitiligo is an autoimmune disease that can run in ...

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September ...